Seroconversions from baseline to ≥96 weeks1,2
Suspected baseline infections: 1 (DESCOVY) and 4 (FTC/TDF)
Seroconversions at other timepoints2,3
-
Primary endpoint analysis: 7 (DESCOVY) vs 15 (FTC/TDF)
- Primary analysis: when 100% of participants reached Week 48 and ≥50% reached Week 96
-
Baseline to ≥144 weeks analysis:
- 2 additional seroconversions occurred in the DESCOVY arm (n=2070)
- 1 additional seroconversion occurred in the initially assigned FTC/TDF arm (n=2115)
- Median intracellular drug levels were substantially lower in participants infected with HIV-1 at the time of diagnosis vs uninfected, matched control participants. Values for 1 participant in the DESCOVY arm are not available
Counsel individuals to strictly adhere to the one tablet, once-daily dosing schedule, as efficacy is strongly correlated with adherence.2
*Seroconversion was observed in 1 person in the FTC/TDF arm with missing DBS sample at the visit of HIV-1 diagnosis; a DBS sample collected 7 weeks prior to the diagnosis showed TFV-DP levels indicating high adherence at that time.4
The efficacy of
DESCOVY is strongly correlated to
adherence to daily dosing.2
You may also be interested in:
DBS=dried blood spot; FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; TFV-DP=tenofovir diphosphate.
